| Registry | NCT07837726 |
|---|---|
| Status | Not yet recruiting |
| Phase | Phase 2 |
| Study type | Interventional; na, single group, masking: none, treatment |
| Enrollment | 6 (Estimated) |
| Sponsor | Thiogenesis Therapeutics, Inc. (Industry) |
| Conditions | Nephropathic Cystinosis, Cystinosis |
| Interventions | TTI-0102 (cysteamine-pantetheine disulfide) (Drug) |
| Dates | start 2026-10-01 (estimated), primary completion 2026-12-01 (estimated), completion 2027-03-01 (estimated), first posted 2026-09-23, last updated 2026-09-23 |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Nephropathic Cystinosis All trials for Cystinosis All trials of TTI-0102 (cysteamine-pantetheine disulfide)
White blood cell (WBC) cystine levels serve as the primary therapeutic target for monitoring cysteamine treatment in cystinosis, with a goal of <1.9 nmol ½ cystine/mg protein as measured 5-6 hours post-dose when treated with immediate-release formulation, Cystagon® , or 11-12 hours post-dose when treated with delayed-release formulation, Procysbi®, using UCSD granulocyte assay.
Although cysteamine dosing in cystinosis has traditionally been individualized based on WBC cystine levels, the FDA-approved Cystagon® prescribing information now includes an approximate recommended maintenance dose of 1.30 g/m²/day. When this dosing strategy is plotted against body weight, it aligns with the dosing regimen of TTI-0102 that was found effective in mitochondrial diseases, demonstrating a linear relationship between dose and weight.
The main objective of this study is to demonstrate that administration of a single dose of 60 ± 5 mg/kg/day of TTI-0102 (\~26 mg/kg cysteamine base equivalent) allows maintenance of WBC cystine at <1.9 nmol ½ cystine/mg protein over 24 hours as determined by UCSD granulocyte assay.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| TTI-0102 (cysteamine-pantetheine disulfide) | Experimental | Drug: TTI-0102 (cysteamine-pantetheine disulfide) | Given once daily for 7 days |
Sex: All, ages: 18 Years to 65 Years
Inclusion Criteria: * Adults aged 18-65 years with a confirmed diagnosis of cystinosis based on clinical features and/or genetic testing, with or without history of kidney transplantation. * Currently treated with a stable dose of Cystagon® or Procysbi® for at least 3 months prior to enrollment. * Body weight between 50 kg and 80 kg at screening. * Able to attend all required study visits and comply with study procedures, including blood draws over a 24-hour period. * Able to provide informed consent in English. * The first 3 patients must have WBC cystine levels over the last year no more than 50% greater than the upper limit of target level Exclusion Criteria: * Known hypersensitivity or allergy to cysteamine, pantetheine, TTI-0102, or any excipients in the study drug. * Clinically significant uncontrolled medical conditions (e.g., unstable cardiac, hepatic, or renal disease) that, in the investigator's judgment, would increase risk or interfere with study participation. * Participation in another interventional clinical trial within 30 days prior to screening. * Any condition that, in the investigator's opinion, would make the participant an unsuitable candidate (e.g., inability to comply with procedures, significant cognitive impairment, active substance use disorder). * Any patient who is pregnant, plans to become pregnant or is unwilling to use contraceptive measures during study participation.